Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.
Authors
Marcia S. Brose
Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Marcia S. Brose, Nicholas J. Vogelzang, Christopher DiSimone, Sharad K. Jain, Donald A. Richards, Carlos A. Encarnacion, Drew W. Rasco, Robert Charles Shumaker, Corina E. Dutcus, Daniel E. Stepan, Matthew Guo, Emmett V. Schmidt, Matthew H. Taylor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02501096
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 16)
DOI
10.1200/JCO.2019.37.8_suppl.16
Abstract #
16
Poster Bd #
A9
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2018 ASCO Annual Meeting
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
First Author: Matthew H. Taylor
Poster
2018 ASCO Annual Meeting
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
First Author: Vicky Makker
Poster
2020 ASCO Virtual Scientific Program
Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Lillian L. Siu